Compare SFBC & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBC | CNTX |
|---|---|---|
| Founded | 1953 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.2M | 102.9M |
| IPO Year | N/A | 2021 |
| Metric | SFBC | CNTX |
|---|---|---|
| Price | $43.42 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 6.4K | ★ 702.1K |
| Earning Date | 01-28-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ 74.62 | N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $38,709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.92 | ★ N/A |
| Revenue Growth | ★ 10.38 | N/A |
| 52 Week Low | $43.80 | $0.49 |
| 52 Week High | $55.85 | $1.55 |
| Indicator | SFBC | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.96 | 65.30 |
| Support Level | $44.20 | $1.07 |
| Resistance Level | $44.99 | $1.10 |
| Average True Range (ATR) | 0.40 | 0.09 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 29.91 | 93.81 |
Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.